The ErbB1-dependent effect of recombinant epidermal growth factor (rEGF) against lapatinib-induced cytotoxicity in Caco-2 human intestinal cells / Raja Nur Firzanah Syaza Raja Sharin ... [et al.]
Lapatinib, an orally administered dual ErbB1 and ErbB2 tyrosine kinase inhibitor, is an FDA-approved treatment for ErbB2-positive breast tumour. However, diarrhoea is one of the major drawbacks for this treatment. Incidence of lapatinib-induced diarrhoea (LID) has been reported as high as 58-78% of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Universiti Teknologi MARA, Pulau Pinang,
2022-09.
|
| Subjects: | |
| Online Access: | Link Metadata |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|